Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected] Learn more

pET-Cas9-NLS-6xHis Citations (3)

Plasmid Article: Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo.
Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, Maeder ML, Joung JK, Chen ZY, Liu DR Nat Biotechnol. 2015 Jan;33(1):73-80. doi: 10.1038/nbt.3081. Epub 2014 Oct 30.
PubMed Journal

Articles Citing pET-Cas9-NLS-6xHis

Articles
Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Wang M, Zuris JA, Meng F, Rees H, Sun S, Deng P, Han Y, Gao X, Pouli D, Wu Q, Georgakoudi I, Liu DR, Xu Q. Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):2868-73. doi: 10.1073/pnas.1520244113. Epub 2016 Feb 29. PubMed
Extensive CRISPR RNA modification reveals chemical compatibility and structure-activity relationships for Cas9 biochemical activity. O'Reilly D, Kartje ZJ, Ageely EA, Malek-Adamian E, Habibian M, Schofield A, Barkau CL, Rohilla KJ, DeRossett LB, Weigle AT, Damha MJ, Gagnon KT. Nucleic Acids Res. 2019 Jan 25;47(2):546-558. doi: 10.1093/nar/gky1214. PubMed
Rationally Designed Anti-CRISPR Nucleic Acid Inhibitors of CRISPR-Cas9. Barkau CL, O'Reilly D, Rohilla KJ, Damha MJ, Gagnon KT. Nucleic Acid Ther. 2019 Jun;29(3):136-147. doi: 10.1089/nat.2018.0758. Epub 2019 Apr 16. PubMed

If you have published an article using this plasmid, please email us at [email protected] to have your article added to this page.